Intellia Therapeutics, Inc. (NTLA)
| Market Cap | 1.77B +156.4% |
| Revenue (ttm) | 67.67M +16.9% |
| Net Income | -412.69M |
| EPS | -3.81 |
| Shares Out | 118.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,086,412 |
| Open | 14.58 |
| Previous Close | 14.16 |
| Day's Range | 14.49 - 15.14 |
| 52-Week Range | 6.80 - 28.25 |
| Beta | 1.99 |
| Analysts | Buy |
| Price Target | 20.45 (+36.79%) |
| Earnings Date | May 7, 2026 |
About NTLA
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an alloge... [Read more]
Financial Performance
In 2025, Intellia Therapeutics's revenue was $67.67 million, an increase of 16.92% compared to the previous year's $57.88 million. Losses were -$412.69 million, -20.49% less than in 2024.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price target is $20.45, which is an increase of 36.79% from the latest price.
News
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial
Intellia Therapeutics Inc. (NASDAQ: NTLA) shares are up on Monday following the FDA's decision to lift the clinical hold on its MAGNITUDE Phase 3 clinical trial.
US FDA lifts clinical hold on Intellia's heart disease gene therapy trial
Intellia Therapeutics said on Monday the U.S. Food and Drug Administration has removed a clinical hold on the late-stage clinical trial for its experimental gene therapy for a heart disease.
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing ...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing a...
Intellia Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder
The U.S. Food and Drug Administration (FDA) on Tuesday said it removed the clinical hold on Intellia Therapeutics Inc.‘s (NASDAQ: NTLA) Investigational New Drug application (IND) for the MAGNITUDE-2 P...
US FDA lifts clinical hold on Intellia's nerve disease trail
Intellia Therapeutics said on Tuesday that the U.S. Food and Drug Administration has lifted a clinical hold on one of its gene therapy late-stage trial, allowing the company to resume testing its expe...
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
CAMBRIDGE, Mass., Nov. 08, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
US FDA places clinical hold on Intellia's two gene-editing treatment trials
Intellia Therapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its two late-stage trials testing an experimental gene-editing therapy for a rare disea...
Intellia pauses late-stage trials of gene-editing treatment after serious liver event
Intellia Therapeutics said on Monday it has temporarily stopped dosing and screening patients in two late-stage studies of its one-time gene-editing treatment for a heart condition after a patient exp...
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary...
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther...
Why big players are pouring millions in THIS biotech stock
Intellia Therapeutics (NASDAQ: NTLA) has been getting a lot of buzz lately among investors who follow the biotech space. The company uses CRISPR gene editing technology to develop treatments, and whil...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Pr...
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera...